Publications by authors named "Christina A Graham"
Article Synopsis
- Tumor-induced osteomalacia (TIO) is a rare condition caused by tumors that lower phosphate levels in the body, negatively impacting bone health and overall physical function.
- A phase 2 trial (UX023T-CL201) showed that after 48 weeks of burosumab treatment, patients experienced restored phosphate levels and significant improvements in skeletal health, mobility, and quality of life.
- An analysis of exit interviews from 8 participants indicated that managing pain and fatigue was crucial, with notable improvements reported after treatment, highlighting the importance of patient perspectives on treatment benefits beyond standard measurements.
Significance: Presbyopia typically occurs around 40 years of age and affects approximately one-quarter of the global population. Up to October 2021, there were no approved pharmacotherapies for presbyopia, and common treatments, such as glasses, can have disadvantages for individuals' health-related quality of life.
Purpose: This study aimed to document the experience of living with and managing presbyopia, identify perspectives on treatment options, and determine whether there is an unmet need in the treatment landscape.